Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Lascoux

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
AIDS (London, England)|August 11, 2020
Correlation of serum hepatitis B core-related antigen with hepatitis B virus total intrahepatic DNA and covalently closed circular-DNA viral load in HIV-hepatitis B coinfectionLorenza N C Dezanet, Sarah Maylin, Audrey Gabassi, et al.
Journal of Hepatology|June 3, 2014
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG studyPatrick Miailhes, Marianne Maynard-Muet, Fanny Lebossé, et al.
Journal of Medical Virology|October 4, 2024
Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023Marie-Laure Chaix, Laura Terracol, Marie-Laure Nere, et al.
Scientific Reports|February 14, 2020
Characterization of HIV-1 diversity in various compartments at the time of primary infection by ultradeep sequencingGéraldine Gaube, Alix Armero, Maud Salmona, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 21, 2018
Nadir CD4 Is Negatively Associated With Antinuclear Antibody Detection in HCV/HIV-Coinfected PatientsIsabelle Poizot-Martin, Eric Rosenthal, Camille Gilbert, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 18, 2015
Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH)Maria Patrizia Carrieri, Lawrence Serfaty, Antoine Vilotitch, et al.
The Journal of Antimicrobial Chemotherapy|June 28, 2022
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trialAntoine Chéret, Rebecca Bauer, Vincent Meiffrédy, et al.
AIDS (London, England)|June 5, 2007
Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY)Lionel Piroth, Damien Sène, Stanislas Pol, et al.
AIDS (London, England)|November 26, 2019
Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infectionRaphael Veil, Isabelle Poizot-Martin, Jacques Reynes, et al.
Antiviral Therapy|October 12, 2012
Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohortMarc-Arthur Loko, Firouze Bani-Sadr, Marc-Antoine Valantin, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
AIDS (London, England)|August 11, 2020
Correlation of serum hepatitis B core-related antigen with hepatitis B virus total intrahepatic DNA and covalently closed circular-DNA viral load in HIV-hepatitis B coinfectionLorenza N C Dezanet, Sarah Maylin, Audrey Gabassi, et al.
Journal of Hepatology|June 3, 2014
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG studyPatrick Miailhes, Marianne Maynard-Muet, Fanny Lebossé, et al.
Journal of Medical Virology|October 4, 2024
Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023Marie-Laure Chaix, Laura Terracol, Marie-Laure Nere, et al.
Scientific Reports|February 14, 2020
Characterization of HIV-1 diversity in various compartments at the time of primary infection by ultradeep sequencingGéraldine Gaube, Alix Armero, Maud Salmona, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 21, 2018
Nadir CD4 Is Negatively Associated With Antinuclear Antibody Detection in HCV/HIV-Coinfected PatientsIsabelle Poizot-Martin, Eric Rosenthal, Camille Gilbert, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 18, 2015
Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH)Maria Patrizia Carrieri, Lawrence Serfaty, Antoine Vilotitch, et al.
The Journal of Antimicrobial Chemotherapy|June 28, 2022
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trialAntoine Chéret, Rebecca Bauer, Vincent Meiffrédy, et al.
AIDS (London, England)|June 5, 2007
Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY)Lionel Piroth, Damien Sène, Stanislas Pol, et al.
AIDS (London, England)|November 26, 2019
Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infectionRaphael Veil, Isabelle Poizot-Martin, Jacques Reynes, et al.
Antiviral Therapy|October 12, 2012
Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohortMarc-Arthur Loko, Firouze Bani-Sadr, Marc-Antoine Valantin, et al.
Pageof 8